


MEVAC™

MULTI ADENO

IMMUNO
COMPETENCE



Inactivated trivalent vaccine against Inclusion Body Hepatitis and Hydropericardium Hepatitis Syndrome

INTRODUCTION

Fowl adenoviruses (FAdVs) are common pathogens of poultry, causing a variety of diseases such as inclusion body hepatitis (IBH), hydropericardium syndrome (HPS), and gizzard erosion. FAdVs are classified into five species (FAdV-A to FAdV-E) and more than 12 serotypes based on their hexon and fiber genes.¹

FAdV-A and FAdV-C primarily cause respiratory diseases in poultry, while FAdV-D is associated with IBH, a severe liver disease characterized by the presence of eosinophilic intranuclear inclusion bodies in hepatocytes. IBH occurs in broiler and layer chickens, causing significant economic losses to the poultry industry worldwide. Clinical signs of IBH include anorexia, depression, increased thirst, yellow diarrhea, and increased mortality rates.¹

Effective control and prevention of IBH rely on accurate diagnosis and understanding of the epidemiology and pathogenesis of FAdV-D. Improved knowledge of FAdV-D infection dynamics and host-virus interactions will facilitate the development of new diagnostic tools and vaccination strategies for the control of IBH.¹

COMPOSITION (before inactivation)

- Inactivated Fowl adenovirus, species C, serotype 4 [ME/FAdV-4] $\geq 5.0 \log_{10} \text{TCID}_{50}/\text{dose}$.
- Inactivated Fowl adenovirus, species D, serotype 11 [F563] $\geq 5.0 \log_{10} \text{TCID}_{50}/\text{dose}$.
- Inactivated Fowl adenovirus, species E serotype 8 [F422] $\geq 5.0 \log_{10} \text{TCID}_{50}/\text{dose}$.

TARGET SPECIES

Chickens.

INDICATIONS

For the immunization of chickens to protect against the clinical signs and mortality associated with inclusion body hepatitis and hydropericardium hepatitis syndrome.

VACCINATION PROGRAM

Birds can be vaccinated from seven days of age onwards, as per advice from your poultry veterinarian.

WITHDRAWAL

Zero days.

CONSIDERATIONS

- The vaccine should not be used if chickens are diseased or immunosuppressed.
- Do not mix with any other veterinary medicinal product.
- No side-effect has been observed during the rearing period following administration of double the recommended dose of vaccine.
- The safety of the veterinary medicinal product has not been established during lay.
- Vaccine bottles shall be shaken well before use.
- Use sterile injection equipment


VACCINE PREPARATION

- Vaccine shall be reconstituted with sterile water free from disinfectant and/or antiseptic.
- Shake the reconstituted lyophilisate until complete resuspension before administration.
- Do not administer less than the recommended dosage.
- Read instructions for appropriate dilution.

MEVAC™

MULTI ADENO

IMMUNO
COMPETENCE



Inactivated trivalent vaccine against Inclusion Body Hepatitis
and Hydropericardium Hepatitis Syndrome



PRESENTATION

MEVAC™ MULTI ADENO is packed and presented in 500 mL (1000 doses) polyethylene terephthalate (PET) bottles.

DOSAGE

The vaccine dose (0.5 mL/bird) should be administered subcutaneously in the lower part of the neck or intramuscularly in the thigh or breast muscles.

ADMINISTRATION

Before use, the vaccine should be shaken well to ensure proper mixing. Sterile injection equipment should be used to avoid contamination.

- Subcutaneous injection: in the lower part of the neck. The needle should be inserted just under the skin in a direction away from the head and in a straight line with the neck.
- Intramuscular injection: in the breast muscles by inserting the needle with a 45° angle to avoid intraperitoneal injection.

STORAGE PRECAUTIONS

- Store and transport refrigerated (+2°C to +8°C).
- Do not freeze.
- Store in a dry place protected from direct sunlight.
- Do not use this product after the expiry date.
- Shelf life after first opening the bottle: 3 hours.

References

1. Elena Mettifogo et al., *Fowl adenovirus Group 1 as a causal agent of inclusion body hepatitis/hydropericardium syndrome (IBH/HPS) outbreak in brazilian broiler flocks*, *Livestock Diseases*, 2014

For further information please contact us:

kemin.biologics@kemin.com

or visit:

kemin.com/eu/en/markets/vaccines



Kemin Industries, Inc. and its group of companies 2024.
All rights reserved. ™™ Trademark of Kemin Industries, Inc., U.S.A. Certain statements, product labelling and claims may differ by geography or as required by local governmental regulations.

PTP-12238